The ProMISe database is the data management system developed by the European Group for Blood and Marrow Transplantation (EBMT). Data of haematological stem cell transplantations (HSCT) performed within EBMT centres are collected for the purpose of the EBMT activity survey and other retrospective studies. All data are entered into the PROMISE database through the Med A and Med B forms. Given the great number and high quality of items collected as part of Med B, we hypothesized that this may represent a useful tool as a Clinical Research Form (CRF) for an academic prospective study assessing a novel reduced toxicity conditioning regimen (ongoing protocol multicenter phase 2 study called "ITT08-01" sponsored by the university hospital of Nantes, identifi ed NCT00841724). In order to establish the relevance of this approach, we fi rst analyzed Med B data for allogeneic HSCT patients and compared it to inclusion and evaluation criteria according to the above mentioned protocol. We found that only the following information were missing: weekly analysis of hematological recovery, monitoring of chimerism and adverse events' grade. Therefore, we created an additional specifi c study database with this missing data. In all, the investigators had to complete both the PROMISE database and the study specifi c additional database. The PROMISE data were transferred every week to the study database, using an automatic pre-programmed export. In order to retrieve only the information of the patients included within study ITT08-01, patients were identifi ed with a specifi c trial number in PROMISE. Interestingly, the 2 other sites participating to the study were able to allow the same retrieval procedure of their data. Using such simplifi ed approach, we were able to save time and resources by avoiding the same input in two different databases, for the patients transplanted according to the protocol and allowing performing immediate statistical analyses from a single fi le. Also, regular monitoring of study ITT08-01 according to Good Clinical Practice criteria, allowed indirectly increasing the quality of data and more frequent follow up in the PROMISE database. This pilot experience shows that the PROMISE database can be used for a wide variety of HSCT academic prospective studies at a multicenter level. Currently, the same approach is performed for other HSCT trials in our centre. HSCT type: All years: 58% are autologous SCT (ASCT); 42% allogeneic SCT (AlloSCT). Gender: All years, All transplants: males = 61%, female = 39%. Stem cell source: Peripheral blood (PB) = 64%, bone marrow (BM) 35%, cord blood (CB) 1%. AlloSCT stem cell source is BM 67%, PB 26%, CB < 1%. For ASCT, PB = 74%, BM 33%, and CB < 0.003%. Use of PB has increased since the 80's, particularly for ASCT. Use of BM has decreased after 2000, particularly in AlloSCT. CB AlloSCT has increased since 1990. Age at HSCT: Median age is 42 years (range 0-83) across all decades. Median age for ASCT is 49 yrs (0-83) and 32 yrs (0-44) for AlloSCT. Age at SCT has increased signifi cantly (P < 0.001) for AlloSCT and ASCT. SCT in children (< 18 yrs) increased until 2000 but has since decreased. This may refl ect missing registrations. A signifi cant increase in SCT in the > 60 yrs occurred (P < 0.001). Donor: Identical siblings account for 55% and unrelated donors (UD) for 37% of AlloSCT, with a signifi cant increase (P < 0.001) in UD over the years. Indications: Multiple Myeloma accounts for 21% of all activity with 19% for Non-Hodgkin's Lymphoma. Both indications increased signifi cantly (P < 0.001), and are predominantly ASCT. SCT for Chronic Myeloid Leukaemia has decreased signifi cantly (P < 0.0001) since 2000. Median time from diagnosis to SCT is 1 year (range 0-61); and has remained consistent over time for both ASCT (0-57) and AlloSCT (0-61). Outcomes: Disease accounts for 55% of deaths. Non relapse mortality (NRM) rate at 5y is 31% for AlloSCT and 13% for ASCT for all years. There is a signifi cant reduction in NRM over time at 1 yr: Allo = 80's (39%), 2000's (22%) P < 0.0001, Auto = 80's (13%), 2000's (6%) P < 0.0001. Median Overall Survival (OS) for all years for AlloSCT is 3 yrs, 5 yrs for ASCT, and has increased signifi cantly (P < 0.001). Median Progression Free Survival (PFS) for all years for is 1 year for AlloSCT and 2 years for ASCT. Conclusion: SCT has increased. We see a signifi cant decrease in NRM and an increase in survival between the epochs. Increased survival may refl ect patient selection. Comparative analyses with other National Registries would be of interest.
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Objectives: The comparison of haematopoietic stem cell transplantation (SCT) and conventional chemotherapy is an area where careful statistical methodological approaches are necessary to avoid biased results. In addition to selection bias, patients have to survive long enough to receive SCT (waitingtime-to-transplant). Furthermore, SCT is expected to increase early mortality due to transplant-associated complications, but may result in a better long-term outcome (non-proportional hazards). In this case, standard methods like log-rank test and Cox regression models can be completely inappropriate for the assessment of survival differences. Values and limitations of several approaches will be discussed and illustrated with exemplary data. Methods: Frequently used methods to account for waiting-timeto-transplant are the so-called landmark analysis and the Cox model including time-dependent covariates. Non-proportional hazards can be handled by extensions of the Cox-model, like weighted Cox regression and time varying effects, the comparison of survival curves at or after fi xed time points, simultaneous confi dence bounds for the difference in survival and Cure models. Results: Ignoring the time-dependent nature of SCT, yields to biased effect size estimation in favour of SCT. Thus, it is essential to account for the waiting-time-bias. For this purpose, the inclusion of time-dependent covariates is more effi cient than landmark analysis. With non-proportional hazards, short-and long-term treatment effects are different. Often, researchers focus on the treatment with better long-term survival. For this, proper statistical methods have to focus on the long-term outcome. In contrast to the Cox model and its extensions, the other approaches directly address long-term outcome. However, they also have limitations: they either depend on the choice of specifi c time points, or they are ineffi cient. In the presence of cured individuals, Cure models do effi ciently refl ect the main interest of long-term outcome without the need for an arbitrary time point. However, they do not allow for time-dependent covariates. Conclusion: For the comparison of SCT and chemotherapy, it is important that analyses are adjusted for waiting-time-to-transplant without relying on the proportional hazards assumption. Otherwise the results may be seriously biased in favour or to the disadvantage of SCT. In addition the analysis should address the exact research question of interest, e.g. long-term outcome.
P1037
EUROCET: the registry of the competent authorities for tissues and cells M. Mareri, A. Ghirardini, P. Di Ciaccio, F. Vespasiano, A. Nanni Costa Italian National Transplant Centre (Rome, IT) Objectives: According to Article 10 of Directive 2004/23/ EC, Member States (MS) and the European Commission (EC) should establish a network linking the national tissue establishment (TEs) registers. This network is made by EUROCET, a registry of national tissue establishments and activity reports, managed by the Italian National Transplant Centre. EUROCET was endorsed by the EC as the Registry of the European Competent Authorities for tissues and cells and the point of reference to collect offi cial data on tissues, hematopoietic progenitor cells (HPC) and cells for assisted reproduction (ART). Methods: We have created a website, where CAs publish: TEs authorized to carry out the activities foreseen in the Directive; data on donation, procurement, banking and transplantation of tissues, HPC and ART. We collaborate with EBMT for the exchange of annual HPC data on transplantation activity. Results: There are 33 countries in Eurocet: all 27 MS, 3 Candidates, and 3 other countries (Figure 1 ). There are 55 CAs: 22 for tissues, HPC and ART; 18 for tissues and HPC; 3 only for tissues; 2 only for HPC; 5 only for ART and 5 for other. 91% (30/33) of countries has identifi ed CA for HPC: 25/27 MS, 2/3 candidates and 3/3 other countries. 2.246 TEs are recorded in EUROCET: 439 for tissues, 494 for ART and 1.313 for HPC. There are 1.313 TEs for HPC registered from 26 countries (23 MS, 2 Candidates, and 1 other country): 37.6% (494/1.313) centres for transplant, 20.9% (274/1.313) for retrieval, 13.3% (174/1.313) for donation, 23.6% (310/1.313) cord blood donation centres, 4.6% (61/1.313) cord blood banks. The annual data for HPC are related to: potential donors and surveys made in the registrers, donation activity, cord blood banking, transplantation activity per origin, per pathology and S330 per each transplant centre. In 2009, 23 countries (20 MS and 3 other) sent HPC data. Concerning transplantation activity, the collaboration with EBMT allowed to integrate Eurocet data completing the European scenario (Figure 2 ). The list of TEs and all data activity have been published on www.eurocet.org. Conclusions: Eurocet is the offi cial network of the CAs for the list of TEs for tissues, HPC and ART and the report of activities for organ, tissue and cell. Eurocet website allows all European and extra-European institutions, patients, and citizens to obtain information on real-time. EBMT-Eurocet collaboration can increase public awareness regarding the social value of donation.
